Nanotechnology-Based Targeting of mTOR Signaling in Cancer

Mee-Sup Yoon Department of Molecular Medicine, School of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Republic of KoreaCorrespondence: Mee-Sup Yoon Tel +82-32-899-6067Fax +82-32-899-6039Email msyoon@gachon...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Yoon MS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	mammalian target of rapamycin cancer rapalogs mtor kinase inhibitor rapa-links nanotechnology nanoparticles Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d2a6893fdadb4cce8f8efde3d73d48de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d2a6893fdadb4cce8f8efde3d73d48de
record_format	dspace
spelling	oai:doaj.org-article:d2a6893fdadb4cce8f8efde3d73d48de2021-12-02T08:28:39ZNanotechnology-Based Targeting of mTOR Signaling in Cancer1178-2013https://doaj.org/article/d2a6893fdadb4cce8f8efde3d73d48de2020-08-01T00:00:00Zhttps://www.dovepress.com/nanotechnology-based-targeting-of-mtor-signaling-in-cancer-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Mee-Sup Yoon Department of Molecular Medicine, School of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Republic of KoreaCorrespondence: Mee-Sup Yoon Tel +82-32-899-6067Fax +82-32-899-6039Email msyoon@gachon.ac.krAbstract: Mammalian target of rapamycin (mTOR) is a master regulator of cell growth and metabolism, which is activated in response to intra- and extracellular signals, including nutrients, growth factors, and cellular energy levels. The frequent dysregulation of mTOR signaling in cancer makes it an attractive therapeutic target, and several types of mTOR inhibitors have been developed. Nanoparticle-based mTOR modulators are predicted to target various cancers and deliver as well as release drugs in a controlled manner, resulting in enhanced bioavailability and reduced side effects. This mini-review is focused on the molecular mechanism of nanoparticle-based mTOR modulator action as well as the current development of mTOR inhibitors using nanoparticles. Understanding the biological function of nanoparticle-based mTOR modulators will contribute to the development of efficient nano-therapeutics for the treatment of cancers.Keywords: mammalian target of rapamycin, cancer, rapalogs, mTOR kinase inhibitor, RapaLinks, nanotechnology, nanoparticlesYoon MSDove Medical Pressarticlemammalian target of rapamycincancerrapalogsmtor kinase inhibitorrapa-linksnanotechnologynanoparticlesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 15, Pp 5767-5781 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	mammalian target of rapamycin cancer rapalogs mtor kinase inhibitor rapa-links nanotechnology nanoparticles Medicine (General) R5-920
spellingShingle	mammalian target of rapamycin cancer rapalogs mtor kinase inhibitor rapa-links nanotechnology nanoparticles Medicine (General) R5-920 Yoon MS Nanotechnology-Based Targeting of mTOR Signaling in Cancer
description	Mee-Sup Yoon Department of Molecular Medicine, School of Medicine, Lee Gil Ya Cancer and Diabetes Institute, Department of Health Sciences and Technology, GAIHST, Gachon University, Incheon 21999, Republic of KoreaCorrespondence: Mee-Sup Yoon Tel +82-32-899-6067Fax +82-32-899-6039Email msyoon@gachon.ac.krAbstract: Mammalian target of rapamycin (mTOR) is a master regulator of cell growth and metabolism, which is activated in response to intra- and extracellular signals, including nutrients, growth factors, and cellular energy levels. The frequent dysregulation of mTOR signaling in cancer makes it an attractive therapeutic target, and several types of mTOR inhibitors have been developed. Nanoparticle-based mTOR modulators are predicted to target various cancers and deliver as well as release drugs in a controlled manner, resulting in enhanced bioavailability and reduced side effects. This mini-review is focused on the molecular mechanism of nanoparticle-based mTOR modulator action as well as the current development of mTOR inhibitors using nanoparticles. Understanding the biological function of nanoparticle-based mTOR modulators will contribute to the development of efficient nano-therapeutics for the treatment of cancers.Keywords: mammalian target of rapamycin, cancer, rapalogs, mTOR kinase inhibitor, RapaLinks, nanotechnology, nanoparticles
format	article
author	Yoon MS
author_facet	Yoon MS
author_sort	Yoon MS
title	Nanotechnology-Based Targeting of mTOR Signaling in Cancer
title_short	Nanotechnology-Based Targeting of mTOR Signaling in Cancer
title_full	Nanotechnology-Based Targeting of mTOR Signaling in Cancer
title_fullStr	Nanotechnology-Based Targeting of mTOR Signaling in Cancer
title_full_unstemmed	Nanotechnology-Based Targeting of mTOR Signaling in Cancer
title_sort	nanotechnology-based targeting of mtor signaling in cancer
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/d2a6893fdadb4cce8f8efde3d73d48de
work_keys_str_mv	AT yoonms nanotechnologybasedtargetingofmtorsignalingincancer
_version_	1718398510477344768

Nanotechnology-Based Targeting of mTOR Signaling in Cancer

Ejemplares similares